Key Takeaways

  • In the COURAGE phase 2 trial, people with obesity on semaglutide plus placebo lost 6.6% of lean mass in 26 weeks; adding trevogrumab preserved roughly half of that loss (+3.1 perce
  • A trevogrumab–garetosmab combination preserved the most lean mass and cut fat mass a further 11.7%, but 9% had serious adverse events, 32% discontinued and 41% had muscle spasms; t
  • Trevogrumab alone was generally well tolerated; the trial was funded by Regeneron and did not prove that preserved lean mass improves physical function.

The problem hiding inside the weight-loss success story

Drugs like semaglutide produce weight loss on a scale medicine has never had before — but not all of what disappears is fat. A substantial share is lean mass: muscle. For older patients especially, that trade can mean weaker legs, frailer bones and a slower metabolism waiting at the end of the diet. A phase 2 trial published in The Lancet on November 11, called COURAGE, tested whether that muscle loss can be blocked while the fat still comes off.

The drug is trevogrumab, an antibody that blocks GDF8 — better known as myostatin, one of the body's own brakes on muscle growth. A second antibody, garetosmab, blocks a related brake called activin A. The trial enrolled 975 people with obesity at 60 U.S. sites; everyone received semaglutide 2.4 mg weekly, and groups added placebo, trevogrumab at various doses, or trevogrumab plus garetosmab.

The muscle result: loss roughly halved

On semaglutide plus placebo, participants lost 6.6% of their lean mass in 26 weeks. Adding trevogrumab cut that loss substantially — the treatment difference was +3.1 percentage points at the 200 mg dose and +2.7 at 400 mg, meaning the trevogrumab groups kept roughly half the lean mass the placebo group lost. Over 52 weeks in the trial's second part, the higher of two low doses again preserved lean mass (+3.1 points).

The combination went further: trevogrumab plus garetosmab preserved the most lean mass (+4.5 points) and stripped far more fat — an additional 11.7% fat-mass reduction beyond semaglutide alone, with extra weight loss to match. On body composition alone, it was the best result in the trial.

And then, the safety column

The combination is also where the trial turns sobering. In the combo arm, 9% of participants had serious adverse events and 32% stopped treatment; 41% reported muscle spasms, versus 5% on semaglutide plus placebo. Two participants died, both in the combination arm — the investigators identified no causal link to treatment, but the pattern ended the argument: the study's authors conclude the combination "did not have favourable safety and tolerability." Trevogrumab alone, by contrast, was generally well tolerated, with a safety profile similar to placebo.

Two more honesty notes. This is a phase 2 trial funded by Regeneron, the drug's maker. And preserving lean mass on a scan is not the same as proving people end up stronger or healthier — the authors say plainly that whether the better body composition preserves physical function is unproven and needs further study.

Health note: Trevogrumab is experimental and not approved anywhere. If you take a GLP-1 medication, the proven defences for muscle are the unglamorous ones — adequate protein and resistance training — and any concern about strength or frailty belongs in a conversation with your doctor, not a supplement or an off-label drug.

The Twikup Take

COURAGE is the clearest proof yet that the muscle cost of GLP-1 weight loss is a solvable problem — and a clean demonstration that in pharmacology, "more blockade" is not the same as "better." The single-antibody path looks genuinely promising. The combination is a warning label with a trial attached.

Image: Illustrative image.

Sources